{"title":"Secukinumab有效治疗血液透析患者的强直性脊柱炎，无副作用。","authors":"Zewen Zhao, Yuhe Yin, Xiaoying Dong, Qingqing Gao, Haowen Lin, Siqi Peng, Yiming Tao, Sichun Wen, Bohou Li, Qiong Wu, Renwei Huang, Sijia Li, Ting Lin, Hao Dai, Zhuo Li, Lixia Xu, Jianchao Ma, Feng Wen, Zhonglin Feng, Shuangxin Liu, Yanhai Cui","doi":"10.5414/CNCS111717","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints. In recent years, biologic agents have gained increasing popularity in the treatment of AS due to their high targeting specificity and favorable side effect profiles. Among these, secukinumab has emerged as an effective treatment option. However, the safety and efficacy of secukinumab in patients undergoing hemodialysis has not yet been thoroughly verified.</p><p><strong>Case report: </strong>Here, we report the successful treatment of AS with secukinumab in a 36-year-old male patient undergoing hemodialysis. The patient presented with recurrent lumbosacral pain and tested positive for HLA-B27. After treatment, significant improvements were observed in both the imaging characteristics of the synovial joints and the patient's symptoms.</p><p><strong>Conclusion: </strong>This case suggests that secukinumab may have a positive effect on AS in patients on hemodialysis, without apparent adverse effects.</p>","PeriodicalId":510898,"journal":{"name":"Clinical nephrology. Case studies","volume":"13 ","pages":"53-58"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444432/pdf/","citationCount":"0","resultStr":"{\"title\":\"Secukinumab effectively manages ankylosing spondylitis in a hemodialysis patient without side effects.\",\"authors\":\"Zewen Zhao, Yuhe Yin, Xiaoying Dong, Qingqing Gao, Haowen Lin, Siqi Peng, Yiming Tao, Sichun Wen, Bohou Li, Qiong Wu, Renwei Huang, Sijia Li, Ting Lin, Hao Dai, Zhuo Li, Lixia Xu, Jianchao Ma, Feng Wen, Zhonglin Feng, Shuangxin Liu, Yanhai Cui\",\"doi\":\"10.5414/CNCS111717\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints. In recent years, biologic agents have gained increasing popularity in the treatment of AS due to their high targeting specificity and favorable side effect profiles. Among these, secukinumab has emerged as an effective treatment option. However, the safety and efficacy of secukinumab in patients undergoing hemodialysis has not yet been thoroughly verified.</p><p><strong>Case report: </strong>Here, we report the successful treatment of AS with secukinumab in a 36-year-old male patient undergoing hemodialysis. The patient presented with recurrent lumbosacral pain and tested positive for HLA-B27. After treatment, significant improvements were observed in both the imaging characteristics of the synovial joints and the patient's symptoms.</p><p><strong>Conclusion: </strong>This case suggests that secukinumab may have a positive effect on AS in patients on hemodialysis, without apparent adverse effects.</p>\",\"PeriodicalId\":510898,\"journal\":{\"name\":\"Clinical nephrology. Case studies\",\"volume\":\"13 \",\"pages\":\"53-58\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444432/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical nephrology. Case studies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5414/CNCS111717\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology. Case studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/CNCS111717","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Secukinumab effectively manages ankylosing spondylitis in a hemodialysis patient without side effects.
Introduction: Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints. In recent years, biologic agents have gained increasing popularity in the treatment of AS due to their high targeting specificity and favorable side effect profiles. Among these, secukinumab has emerged as an effective treatment option. However, the safety and efficacy of secukinumab in patients undergoing hemodialysis has not yet been thoroughly verified.
Case report: Here, we report the successful treatment of AS with secukinumab in a 36-year-old male patient undergoing hemodialysis. The patient presented with recurrent lumbosacral pain and tested positive for HLA-B27. After treatment, significant improvements were observed in both the imaging characteristics of the synovial joints and the patient's symptoms.
Conclusion: This case suggests that secukinumab may have a positive effect on AS in patients on hemodialysis, without apparent adverse effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
